Intellia Therapeutics (NTLA) Reports Q4 Loss of $0.31/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Intellia Therapeutics (NTLA) Reports Q4 Loss of $0.31/Share

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results

March 14, 2017 7:15 AM EDT

First to demonstrate single dose, in vivo results, showing approximately 97 percent reduction in serum transthyretin protein levelsFurther established a comprehensive platform, including a proprietary lipid nanoparticle delivery system, to accelerate therapeutic developmentExecuted partnering deal with Regeneron Pharmaceuticals, and continued to advance Intellias partnership with Novartis, to support Intellias emerging pipeline with six distinct programs in active research and development, spanning multiple types of genome editingContinued to deploy a diversified approach to maximize CRISPR potential, including pursuing CRISPR... More